BCM
LJPC

BlueCrest Capital Management’s La Jolla Pharmaceutical Company LJPC Stock Holding History

BlueCrest Capital Management’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-18,454
Closed -$642K – 1256
2017
Q3 		$642K Buy
+18,454
New +$593K 0.03% 454

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's LJPC Position: Q4 2017 in Review

BlueCrest Capital Management sold out of La Jolla Pharmaceutical Company (LJPC) in Q4 2017, closing a stake of 18,454 shares — an estimated $642K sold.

BlueCrest Capital Management first reported a position in LJPC in Q3 2017 and held it in 1 quarter. The position peaked at $642K in Q3 2017. 93 funds tracked by Wall St. Rank hold LJPC as of Q4 2017.

  • BlueCrest Capital Management reported no remaining La Jolla Pharmaceutical Company position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 18,454 La Jolla Pharmaceutical Company shares in Q4 2017, an estimated $642K.
  • BlueCrest Capital Management first reported a position in La Jolla Pharmaceutical Company in Q3 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's La Jolla Pharmaceutical Company position peaked at $642K in Q3 2017.
  • 93 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.